198 related articles for article (PubMed ID: 20506333)
21. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
[TBL] [Abstract][Full Text] [Related]
22. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
[TBL] [Abstract][Full Text] [Related]
23. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
Klauss V; Serruys PW; Pilgrim T; Buszman P; Linke A; Ischinger T; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; van Geuns RJ; van Es GA; Kalesan B; Wenaweser P; Jüni P; Windecker S
JACC Cardiovasc Interv; 2011 Aug; 4(8):887-95. PubMed ID: 21851904
[TBL] [Abstract][Full Text] [Related]
24. Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry.
Kim JS; Lee BH; Ko YG; Choi D; Jang Y; Min PK; Yoon YW; Hong BK; Kwon HM; Ahn MS; Lee SH; Yoon JH; Lee BK; Kim BO; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Jung JH; Ryu SK;
Catheter Cardiovasc Interv; 2008 Nov; 72(5):601-7. PubMed ID: 18942123
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
Stone GW; Ellis SG; Colombo A; Grube E; Popma JJ; Uchida T; Bleuit JS; Dawkins KD; Russell ME
JACC Cardiovasc Interv; 2011 May; 4(5):530-42. PubMed ID: 21596326
[TBL] [Abstract][Full Text] [Related]
26. Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets.
Roy P; Torguson R; Okabe T; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LL; Kent KM; Suddath WO; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2007 Aug; 70(2):167-72. PubMed ID: 17503503
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
28. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
[TBL] [Abstract][Full Text] [Related]
29. Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry.
Sgueglia GA; Burzotta F; Trani C; Todaro D; Talarico GP; Niccoli G; Porto I; Leone AM; Coluccia V; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Catheter Cardiovasc Interv; 2011 Mar; 77(4):503-9. PubMed ID: 20602477
[TBL] [Abstract][Full Text] [Related]
30. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
32. Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study.
Park DW; Kim YH; Song HG; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Her SH; Hur SH; Park JS; Kim MK; Choi YS; Kim HS; Cho JH; Lee SG; Park YW; Jeong MH; Lee BK; Lee NH; Lim DS; Yoon J; Seung KB; Shin WY; Rha SW; Kim KS; Tahk SJ; Park BE; Ahn T; Yang JY; Jeong YS; Rhew JH; Park SJ;
Circ Cardiovasc Interv; 2012 Jun; 5(3):365-71. PubMed ID: 22693347
[TBL] [Abstract][Full Text] [Related]
33. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
34. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
[TBL] [Abstract][Full Text] [Related]
36. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
[TBL] [Abstract][Full Text] [Related]
37. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
[TBL] [Abstract][Full Text] [Related]
38. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy.
Wykrzykowska JJ; Räber L; de Vries T; Bressers M; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Regar E; Jüni P; Windecker S; Serruys PW
EuroIntervention; 2009 Aug; 5(3):310-7. PubMed ID: 19736154
[TBL] [Abstract][Full Text] [Related]
39. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
40. Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.
Kim U; Kim DK; Seol SH; Yang TH; Kim DK; Kim DI; Kim DS; Lee SH; Hong GR; Park JS; Shin DG; Kim YJ; Cho YK; Kim HS; Nam CW; Hur SH; Kim KB
Clin Cardiol; 2010 Jun; 33(6):340-4. PubMed ID: 20556803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]